Study Status: RECRUITING
Recruit Status: RECRUITING
Study Type: INTERVENTIONAL
Official Title: Impact of Low Sodium Oxybate on Total Sleep Time in Patients With Idiopathic Hypersomnia
Brief Summary: Low sodium oxybate has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic hypersomnia.
In this study, the researchers want to learn how low sodium oxybate impacts ability of people diagnosed with idiopathic hypersomnia to sleep for long periods of time.
In addition, this study will use novel tools to determine when an individual is awake or asleep.